Bioventus Inc (BVS)
Bioventus Inc. is a healthcare company focused on medical devices for pain relief and musculoskeletal care in the United States and international markets. Its portfolio spans injection-based pain treatments, including intra-articular and hyaluronic acid products, as well as peripheral nerve stimulation devices such as Stimrouter and TalisMann. The company also markets the XCELL PRP System, which processes whole blood to produce platelet-rich plasma, along with surgical and orthopedic products used in bone resection, ultrasonic surgery, and bone fusion procedures. Additional offerings include Exogen for bone stimulation and a range of graft and scaffold products used in orthopedic, neurosurgical, and reconstructive applications. Bioventus sells to healthcare institutions, physicians, patients, distributors, and dealers. The company was founded in 2011 and is headquartered in Durham, North Carolina.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-BVS
|
$14.39
|
22.1% Upside
|
Undervalued
|
$14.80
|
25.5% Upside
|
Undervalued
|
Great
|
—
|
—
|
—
|
0.0%
|
August 11, 2026
|
27.9x
|
5.2x
|
1.7x
|
967.3 M
|
1.092 B
|
22.2%
|
49.2%
|
2.9
|
—
|
353.3%
|
